These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 28984200)

  • 1. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
    Yang XH; Tang F; Shin J; Cunningham JM
    BMC Syst Biol; 2017 Oct; 11(Suppl 5):92. PubMed ID: 28984200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The growth-inhibitory Ndrg1 gene is a Myc negative target in human neuroblastomas and other cell types with overexpressed N- or c-myc.
    Li J; Kretzner L
    Mol Cell Biochem; 2003 Aug; 250(1-2):91-105. PubMed ID: 12962147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma.
    Ochiai H; Takenobu H; Nakagawa A; Yamaguchi Y; Kimura M; Ohira M; Okimoto Y; Fujimura Y; Koseki H; Kohno Y; Nakagawara A; Kamijo T
    Oncogene; 2010 May; 29(18):2681-90. PubMed ID: 20190806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
    Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
    Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of clinical characteristics and molecular signatures of the tumor microenvironment to predict the prognosis of neuroblastoma.
    Cheng H; Zhang L; Yang S; Ren Q; Chang S; Jin Y; Mou W; Qin H; Yang W; Zhang X; Zhang W; Wang H
    J Mol Med (Berl); 2023 Nov; 101(11):1421-1436. PubMed ID: 37712965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
    George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
    J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma.
    Fredlund E; Ringnér M; Maris JM; Påhlman S
    Proc Natl Acad Sci U S A; 2008 Sep; 105(37):14094-9. PubMed ID: 18780787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma.
    Weng Z; Lin J; He J; Gao L; Lin S; Tsang LL; Zhang H; He X; Wang G; Yang X; Zhou H; Zhao H; Li G; Zou L; Jiang X
    Neuro Oncol; 2022 Jun; 24(6):872-885. PubMed ID: 34655293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different regulation of mid-size neurofilament and N-myc mRNA expression during neuroblastoma cell differentiation induced by retinoic acid.
    Di Martino D; Ponzoni M; Cornaglia-Ferraris P; Tonini GP
    Cell Mol Neurobiol; 1990 Sep; 10(3):459-70. PubMed ID: 2123747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN.
    Cohn SL; London WB; Huang D; Katzenstein HM; Salwen HR; Reinhart T; Madafiglio J; Marshall GM; Norris MD; Haber M
    J Clin Oncol; 2000 Nov; 18(21):3604-13. PubMed ID: 11054433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest.
    Yaari S; Jacob-Hirsch J; Amariglio N; Haklai R; Rechavi G; Kloog Y
    Clin Cancer Res; 2005 Jun; 11(12):4321-30. PubMed ID: 15958613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma.
    Woo CW; Tan F; Cassano H; Lee J; Lee KC; Thiele CJ
    Pediatr Blood Cancer; 2008 Feb; 50(2):208-12. PubMed ID: 17420990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low expression of Wnt-5a gene is associated with high-risk neuroblastoma.
    Blanc E; Roux GL; Bénard J; Raguénez G
    Oncogene; 2005 Feb; 24(7):1277-83. PubMed ID: 15592517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical analysis of the Bcl-2 oncoprotein in human neuroblastomas. Comparisons with tumor cell differentiation and N-Myc protein.
    Krajewski S; Chatten J; Hanada M; Reed JC
    Lab Invest; 1995 Jan; 72(1):42-54. PubMed ID: 7837790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification.
    Cohn SL; Salwen H; Quasney MW; Ikegaki N; Cowan JM; Herst CV; Kennett RH; Rosen ST; DiGiuseppe JA; Brodeur GM
    Oncogene; 1990 Dec; 5(12):1821-7. PubMed ID: 2284101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of histone demethylase KDM4B in Myc signaling in neuroblastoma.
    Yang J; AlTahan AM; Hu D; Wang Y; Cheng PH; Morton CL; Qu C; Nathwani AC; Shohet JM; Fotsis T; Koster J; Versteeg R; Okada H; Harris AL; Davidoff AM
    J Natl Cancer Inst; 2015 Jun; 107(6):djv080. PubMed ID: 25925418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global genomic and proteomic analysis identifies biological pathways related to high-risk neuroblastoma.
    Chen QR; Song YK; Yu LR; Wei JS; Chung JY; Hewitt SM; Veenstra TD; Khan J
    J Proteome Res; 2010 Jan; 9(1):373-82. PubMed ID: 19921788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinoic acid decreases targeting of p27 for degradation via an N-myc-dependent decrease in p27 phosphorylation and an N-myc-independent decrease in Skp2.
    Nakamura M; Matsuo T; Stauffer J; Neckers L; Thiele CJ
    Cell Death Differ; 2003 Feb; 10(2):230-9. PubMed ID: 12700651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinoic acid-induced growth arrest and differentiation of neuroblastoma cells are counteracted by N-myc and enhanced by max overexpressions.
    Peverali FA; Orioli D; Tonon L; Ciana P; Bunone G; Negri M; Della-Valle G
    Oncogene; 1996 Jan; 12(2):457-62. PubMed ID: 8570225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.